Mont-Saint-Guibert, Belgium; September 29, 2025, 6:30 pm CET; regulated information / inside information – Celyad Oncology (Euronext: CYAD) (the “Company”), today announces the divestment of the Company’s research facility.
Under the terms of an asset purchase agreement, the Company shall sell its research facility’s equipment and office furniture in Mont-Saint-Guibert, Belgium, for a total consideration of €3 million. The transaction is subject to a number of customary conditions precedent and is anticipated to close in the fourth quarter of this year. Management currently anticipates that this transaction will extend the cash runway of the Company by approximatively three quarters, i.e. into Q3-2026.
